Tesamorelin vs Sermorelin: Choosing the Right Peptide for Your Research Choose Tesamorelin When: The primary research endpoint is visceral adipose tissue (VAT) reduction Rapid, measurable IGF-1 elevation is needed within a short protocol window Studying metabolic syndrome, abdominal obesity, or lipodystrophy models Extended protocol stability is required (tesamorelin resists enzymatic degradation better) Research budget supports a higher-cost compound for a shorter, intensive protocol Choose Sermorelin When: The focus is long-term endocrine system support and hormonal homeostasis Sleep architecture and recovery pathways are the primary study variables Anti-aging, collagen synthesis, or longevity markers are being investigated A physiological, pulsatile GH release pattern is required to preserve feedback loops Cost efficiency over a long-duration protocol is a consideration The comparison extends beyond just these two peptides
Dr Piotr Ozieranski, who researches conflicts of interest at the University of Bath, analysed the ABPIs disclosure database and reports published on Novos Nordisks website, which found: This doesnt mean the studies based on the SELECT trial are unreliable or the results are inaccurate
Nausea and appetite suppression from semaglutide may already reduce your desire to eat, and antibiotics themselves sometimes cause additional GI upset
A change in urine color to bright yellow from the B vitamins, which is normal
